Risankizumab Found Effective for Crohn’s in New Phase 3 Study
In a recent Phase 3 study by AbbVie, Risankizumab (Skyrizi) was found effective for people with moderate to severe Crohn’s. In fact, in both Phase 3 trials patients showed not only clinical remission, but endoscopic response as well at 12 weeks. This study was done in two groups named ADVANCE and MOTIVATE. They had slightly … Read more